OnabotulinumtoxinA for Treatment of Moderate-to-Severe Horizontal Lines and Glabellar Lines from the Subject’s Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study. J of Skin [Internet]. 2017 Oct. 27 [cited 2026 May 2];1(3.1):s82. Available from: https://skin.dermsquared.com/skin/article/view/86